Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Rating of “Hold” from Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have earned an average rating of “Hold” from the six brokerages that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $19.33.

A number of research analysts have recently issued reports on the company. StockNews.com cut Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, April 6th. JPMorgan Chase & Co. cut their target price on Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating on the stock in a research note on Thursday, February 8th.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several large investors have recently made changes to their positions in ENTA. Braidwell LP lifted its holdings in shares of Enanta Pharmaceuticals by 218.7% during the first quarter. Braidwell LP now owns 1,038,310 shares of the biotechnology company’s stock valued at $41,989,000 after purchasing an additional 712,472 shares during the last quarter. Krensavage Asset Management LLC purchased a new position in Enanta Pharmaceuticals in the 1st quarter worth approximately $24,397,000. Assenagon Asset Management S.A. raised its holdings in Enanta Pharmaceuticals by 613.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 631,626 shares of the biotechnology company’s stock worth $7,055,000 after acquiring an additional 543,111 shares during the last quarter. Acadian Asset Management LLC raised its holdings in Enanta Pharmaceuticals by 445.6% in the 3rd quarter. Acadian Asset Management LLC now owns 548,782 shares of the biotechnology company’s stock worth $6,125,000 after acquiring an additional 448,201 shares during the last quarter. Finally, State Street Corp raised its holdings in Enanta Pharmaceuticals by 29.9% in the 2nd quarter. State Street Corp now owns 1,699,428 shares of the biotechnology company’s stock worth $80,332,000 after acquiring an additional 390,842 shares during the last quarter. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA stock opened at $13.32 on Friday. Enanta Pharmaceuticals has a 52-week low of $8.08 and a 52-week high of $37.75. The company has a market capitalization of $281.80 million, a PE ratio of -2.03 and a beta of 0.47. The business’s fifty day moving average is $14.82 and its 200 day moving average is $11.74.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.40). Enanta Pharmaceuticals had a negative net margin of 187.77% and a negative return on equity of 60.38%. The firm had revenue of $18.00 million for the quarter, compared to analysts’ expectations of $22.74 million. On average, sell-side analysts forecast that Enanta Pharmaceuticals will post -4.9 EPS for the current fiscal year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.